Business Wire

Eaton to Supply Breaktor® Circuit Protection Technology to Leading European-Based Vehicle Manufacturer for New EV Models

20.4.2022 13:30:00 EEST | Business Wire | Press release

Share

Power management company Eaton today announced its eMobility business has received a contract to supply its Breaktor® circuit protection technology to a European vehicle manufacturer for use in multiple models of 800-volt battery electric vehicles (BEVs).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220420005070/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eaton’s Breaktor offers fast, safe and reliable protection for high-power battery and inverter systems. (Photo: Business Wire)

The Breaktor technology is a new advanced circuit protection solution for BEVs that combines the function of fuses, pyro switches and contactors into a single coordinated device. As electric vehicle power levels increase, the Breaktor circuit protection solution solves the ever-increasing coordination challenge between fuses and contactors while offering fast, safe and reliable protection for high-power battery and inverter systems.

“To meet EV consumer demand for longer range and faster charging, new EVs have increased power levels, which drives the need for advanced circuit protection for these high-voltage systems,” said Scott Adams, president, eMobility, Eaton. “Our Breaktor technology offers improved EV system safety and reliability with a simplified architecture. In fact, one Breaktor circuit protection unit can replace up to 15 components. We are excited to bring such a critical part of the EV system to this world-class vehicle manufacturer.”

The Breaktor circuit protection technology is an innovative solution that leverages Eaton’s industrial electrical technology and automotive expertise to deliver performance and reliability while simplifying architecture. With a less than 4-millisecond actuation for short-circuit faults up to 900 volts and 25,000 amps, the Breaktor circuit protection technology improves vehicle safety and protects components from any level of overcurrent condition more effectively than traditional circuit protection methods. The Breaktor circuit protection solution is resettable like a circuit breaker, enabling reactivation of the device following a functionality check and reducing cost for both the OEM and consumer.

“In the event of a collision, Eaton’s Breaktor circuit protection technology works in tandem with a vehicle’s safety systems,” Adams said. “It rapidly disconnects the high-voltage battery from the rest of the vehicle for protection and safety in the event of any unsafe condition.”

The Breaktor circuit protection technology provides BEV manufacturers with several additional benefits, including:

  • A self-triggering device that can sense a current spike and interrupt the circuit without the need for any external sensing or triggering.
  • A current-limiting device in the event of a short circuit, improving system-level protection.
  • Operating independently of current direction, which allows for both charging and duty use under full electrical load.
  • Availability in multiple configurations, including voltage levels and multi-pole designs.

The Breaktor circuit protection solution was designed and tested at Eaton’s advanced electrical facility in Bonn, Germany, with sub-production scheduled to begin this year in Gummersbach, Germany, and final assembly to take place in Győr, Hungary.

Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we’re accelerating the planet’s transition to renewable energy, helping to solve the world’s most urgent power management challenges, and doing what’s best for our stakeholders and all of society.

Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye